ZeJing Pharmaceuticals: signed an exclusive marketing service agreement for injectable recombinant human thyroid stimulating hormone.

Zejing Pharmaceutical announcement, the company signed a "Service Agreement" with ATSA, authorizing ATSA as the exclusive market promotion service provider for recombinant human thyrotropin for injection in the People's Republic of China. The company will receive authorization total amount up to 250 million yuan, of which within 30 working days from the effective date of the agreement, ATSA will pay the first installment of 50 million yuan, and after the first indication of the product is approved, ATSA will pay the second installment of 200 million yuan. The company will pay market promotion service fees to ATSA based on double-digit percentages of net sales. Recombinant human thyrotropin for injection is in the stage of drug registration and market approval application.